

Systems biology

IntLIM 2.0: identifying multi-omic relationships dependent on discrete or continuous phenotypic measurements

Tara Eicher ^{1,2}, Kyle D. Spencer^{1,3}, Jalal K. Siddiqui⁴, Raghu Machiraju^{2,5,6} and Ewy A. Mathé^{1,*}

¹Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20892, USA, ²Department of Computer Science and Engineering, The Ohio State University, Columbus, OH 43210, USA, ³Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210, USA, ⁴Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA, ⁵Biomedical Informatics Department, The Ohio State University, Columbus, OH 43210, USA and ⁶Department of Pathology, The Ohio State University, Columbus, OH 43210, USA

*To whom correspondence should be addressed.

Received on January 3, 2023; editorial decision on January 4, 2023; accepted on February 1, 2023

Abstract

Motivation: IntLIM uncovers phenotype-dependent linear associations between two types of analytes (e.g. genes and metabolites) in a multi-omic dataset, which may reflect chemically or biologically relevant relationships.

Results: The new IntLIM R package includes newly added support for generalized data types, covariate correction, continuous phenotypic measurements, model validation and unit testing. IntLIM analysis uncovered biologically relevant gene–metabolite associations in two separate datasets, and the run time is improved over baseline R functions by multiple orders of magnitude.

Availability and implementation: IntLIM is available as an R package with a detailed vignette (<https://github.com/ncats/IntLIM>) and as an R Shiny app (see [Supplementary Figs S1–S6](https://intlim.ncats.io/)) (<https://intlim.ncats.io/>).

Contact: ewy.mathe@nih.gov

Supplementary information: [Supplementary data](#) are available at *Bioinformatics Advances* online.

1 Introduction

In recent years, many biomedical fields have begun to explore multi-omic mechanisms of disease, clinical outcomes and other phenotypic traits. However, integrating and interpreting multi-omic data to discover latent interdependencies remains a challenge (Eicher *et al.*, 2020). We introduce IntLIM 2.0, an R package that uncovers phenotype-dependent linear associations between two types of analytes (e.g. genes and metabolites). IntLIM 2.0 extends IntLIM 1.0 (Siddiqui *et al.*, 2018) to support generalized analyte measurement data types, continuous phenotypic measurement, covariate correction, model validation and unit testing. Several other tools support global multi-omic correlations or phenotype-dependent correlation analysis for either discrete or continuous phenotypic measurements (Fukushima, 2013; Langfelder and Horvath, 2008; Ma *et al.*, 2019; Shi *et al.*, 2019; Siska *et al.*, 2016). IntLIM 2.0 is unique as it supports continuous and discrete phenotypic measurements, and is based on linear models, which allow for adjustment of independent effects (e.g. clinical variables and technical effects).

2 IntLIM functionality

For each pair of analytes in a dataset, IntLIM 2.0 solves Equation (1) in a streamlined manner, where a_i and a_j are measurements for two separate analytes, p is the phenotypic measurement, $C = \{c_1, \dots, c_{|C|}\}$ is a set of continuous or discrete clinical covariates (potential model confounders as determined by data analyst), and $\beta_0 - \beta_3 + |C|$ is a set of coefficients corresponding to the model intercept, a_j , p , the interaction between a_j and p , and additional model covariates. Notably, the order of a_j and a_i may affect the outcome and should be motivated by biology (e.g. effect of gene expression level a_i on metabolite abundance a_j).

$$a_i = \beta_0 + \beta_1 a_j + \beta_2 p + \beta_3 a_j p + \sum_{k=4}^{|C|} \beta_k c_{k-3}. \quad (1)$$

The input to IntLIM 2.0 is described in the [Supplementary Files](#). Users have the option to filter individual analytes by percentage of missing values, mean measurement and coefficient of variation, but




Fig. 1. Schematic of IntLIM 2.0 functionality. New features include filtering by coefficient of variation in *FilterData()*, addition of covariate terms in *RunIntLim()*, filtering by model R^2 in *ProcessResults()*, and the *RunCrossValidation()* and *PermuteIntLim()* functions

it is expected that the sample metadata and analyte measurements have already been otherwise filtered, normalized and/or imputed prior to analysis.

Analyte pairs with significant phenotype-dependent associations are returned and returned using one or more of the following criteria: Benjamini–Hochberg false discovery rate adjusted β_3 P -value, β_3 percentile and coefficient of determination (R^2) value (Supplementary Files). To ensure the validity of the P -value as a measure of significance, it is expected that a_i follows a Gaussian distribution. We note that multiple visualization functions are also included in IntLIM 2.0, including a trendline and residual plot, a newly developed figure of analyte measurements marginalized over phenotype and a plot of sorted β_3 values (Supplementary Files). An overview of the functionality of IntLIM is illustrated in Figure 1.

3 New features

IntLIM 2.0 includes several major expansions to IntLIM 1.0 (Patt et al., 2019; Siddiqui et al., 2018). First, in addition to the *gene ~ metabolite* models supported by IntLIM 1.0, IntLIM 2.0 supports both inter- and intra-omics (e.g. *metabolite ~ metabolite*) models and other types of omics data (e.g. microbial abundance, protein abundance, methylation level or mutation rate) (Do et al., 2015; Langfelder and Horvath, 2008; Van Der Knaap and Verrijzer, 2016). Second, IntLIM 2.0 supports correction for covariates (e.g. batch effects, demographic or clinical covariates). Relatedly, a new option to filter models by R^2 value allows users to evaluate models by goodness of fit. Third, IntLIM 2.0 supports continuous phenotypic measurements (e.g. disease severity, drug response metrics, etc.) in addition to data with two phenotype categories of interest (e.g. case/control). Fourth, IntLIM 2.0 supports model validation using (i) cross-validation and (ii) random permutation models, along with accompanying visualizations described further in Supplementary Files. Finally, the introduction of unit tests using the *testthat* package (Wickham, 2011) makes IntLIM 2.0 more robust to programming errors than IntLIM 1.0.

4 Results

The utility of IntLIM 2.0 is illustrated using datasets with continuous and discrete phenotypic measurements. The NCI-60 dataset (continuous) includes 57 cell lines from NCI-60 (Shoemaker, 2006), each with 17 987 gene expression levels, 280 metabolite abundance levels (Su et al., 2011) and the average drug concentration that inhibits cell growth by 50% (IC_{50}) over 48 h (*drug score*) (Reinhold et al., 2012). The BRCA dataset (discrete) includes 61 tumor and 47 adjacent normal breast tissue samples, each with 20 254 gene expression levels and 536 metabolite abundance levels (Terunuma

Table 1. Summary of IntLIM 2.0 results on NCI-60 and BRCA datasets

Dataset	Filtered analyte count (gene/metabolite)	Significant pair ^a count	Significant pairs with knowledge support ^b
NCI-60	16 188/280	2517	26
BRCA	18 288/536	14 583	555

^aFDR-adjusted P -value < 0.1 for β_3 , $|\beta_3|$ percentile > 0.5, R^2 > 0.2.

^bShared pathway and/or reaction in RaMP-DB 2.0 (Braisted et al., 2022; Zhang et al., 2018).

Table 2. Runtime of IntLIM 2.0 and *lm()* on two separate machines for a reduced dataset

R function	Runtime (Machine 1) (s)	Runtime (Machine 2) (s)
<i>RunIntLim()</i>	12	11
<i>lm()</i>	1622	482

et al., 2014). Patient age and race covariates were adjusted for this dataset. Detailed vignettes on running these models in the NCI-60 and BRCA vignettes are available at tinyurl.com/du5xv5pc and tinyurl.com/2p94sfde, respectively. Results are summarized in Table 1, Supplementary Files and vignettes.

Significant associations found in the NCI-60 data have been implicated in tumor progression and/or treatment: namely, cholesterol with HHAT (Callahan and Wang, 2015) and CDKN1A (Moon et al., 2019). These pairs and 19 pairs with knowledgebase support were insignificant in all 100 permutations of the data (Supplementary Fig. S7), supporting non-randomness. Further, 1778 of the 2517 pairs were significant in at least one leave-one-out cross-validation fold, and 734 were significant in more than half of the folds. Additionally, the BRCA analysis also uncovered associations previously reported using IntLIM 1.0 (Siddiqui et al., 2018); namely, ASNS and glutamine, SLC7A1 and glutamine, and GPT2 and 2-hydroxyglutarate. These pairs and 413 pairs with knowledgebase support were insignificant in all 100 permutations (Supplementary Fig. S8). 19 of the 14 583 pairs were significant in at least one leave-one-out cross-validation fold, which is likely attributable to the smaller sample size.

Runtime of IntLIM 2.0 was considerably faster than the linear mixed model function *lm()* in the *stats* R package when tested on all metabolite levels and the first 100 gene expression levels in the NCI-60 data (Table 2).

Machine 1 is a MacBook Pro laptop running macOS 12.3 with an Intel Core i7 CPU, and Machine 2 is a single compute node of a SLURM high-performance computing cluster running CentOS Linux 7 with 2 allocated Intel Gold 6140 CPU's.

Acknowledgements

This work utilized the computational resources of the NIH HPC Biowulf cluster (<http://hpc.nih.gov>). We thank Elizabeth Baskin for contributing to the R package, Ke Wang and John Braisted for server deployment and repository management, and the NIH Individual Graduate Partnership Program for training and mentoring.

Funding

This work was supported in part by the National Center for Advancing Translational Sciences (NCATS) Informatics Research Core [ZIC TR000410-03].

Conflict of Interest: none declared.

References

- Braisted, J. *et al.* (2022) RaMP-DB 2.0: a renovated knowledgebase for deriving biological and chemical insight from metabolites, proteins, and genes. *Bioinformatics*, **39**, btac726.
- Callahan, B.P. and Wang, C. (2015) Hedgehog cholesterolysis: specialized gatekeeper to oncogenic signaling. *Cancers (Basel)*, **7**, 2037–2053.
- Do, K.T. *et al.* (2015) Network-based approach for analyzing intra- and inter-fluid metabolite associations in human blood, urine, and saliva. *J. Proteome Res.*, **14**, 1183–1194.
- Eicher, T. *et al.* (2020) Metabolomics and multi-omics integration: a survey of computational methods and resources. *Metabolites*, **10**, 202.
- Fukushima, A. (2013) DiffCorr: an R package to analyze and visualize differential correlations in biological networks. *Gene*, **518**, 209–214.
- Langfelder, P. and Horvath, S. (2008) WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics*, **9**, 559.
- Ma, J. *et al.* (2019) Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. *Bioinformatics*, **35**, 3441–3452.
- Moon, S.H. *et al.* (2019) p53 represses the mevalonate pathway to mediate tumor suppression. *Cell*, **176**, 564–580.e19.
- Patt, A. *et al.* (2019) Integration of metabolomics and transcriptomics to identify gene-metabolite relationships specific to phenotype. *Methods Mol. Biol.*, **1928**, 441–468.
- Reinhold, W.C. *et al.* (2012) CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. *Cancer Res.*, **72**, 3499–3511.
- Shi, W.J. *et al.* (2019) Unsupervised discovery of phenotype-specific multi-omics networks. *Bioinformatics*, **35**, 4336–4343.
- Shoemaker, R.H. (2006) The NCI60 human tumour cell line anticancer drug screen. *Nat. Rev. Cancer*, **6**, 813–823.
- Siddiqui, J.K. *et al.* (2018) IntLIM: integration using linear models of metabolomics and gene expression data. *BMC Bioinformatics*, **19**, 81.
- Siska, C. *et al.* (2016) The discordant method: a novel approach for differential correlation. *Bioinformatics*, **32**, 690–696.
- Su, G. *et al.* (2011) Integrated metabolome and transcriptome analysis of the NCI60 dataset. *BMC Bioinformatics*, **12**, S36.
- Terunuma, A. *et al.* (2014) MYC-driven accumulation of 2-hydroxyglutamate is associated with breast cancer prognosis. *J. Clin. Invest.*, **124**, 398–412.
- Van Der Knaap, J.A. and Verrijzer, C.P. (2016) Undercover: gene control by metabolites and metabolic enzymes. *Genes Dev.*, **30**, 2345–2369.
- Wickham, H. (2011) testthat: get started with testing. *R Journal*, **3**, 5–10.
- Zhang, B. *et al.* (2018) RaMP: a comprehensive relational database of metabolomics pathways for pathway enrichment analysis of genes and metabolites. *Metabolites*, **8**, 16.